Study of AZD4144 in people with liver problems
This study tests a new medicine called AZD4144 to see how the body handles it in people with different levels of liver function. It may help doctors understand how to dose the medicine for people with liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and weigh at least 110 pounds (50 kg).
- Your body mass index (BMI) must be between 18 and 45.
- If you have liver disease, it must be stable and you must be on the same medicines for at least 2 weeks before the study.
- You must not have type 1 or type 2 diabetes if you are in the healthy control group.
- You cannot have severe kidney problems, unstable heart or lung conditions, or a history of long QT syndrome.
- You must not be taking certain medications, steroids, or have had live vaccines in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This study tests a new medicine called RAY1225 in people with mild or moderate liver problems compared to those with healthy livers. It helps researchers understand how the liver affects the medicine, which could lead to safer dosing.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.